News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Summit Pharmaceuticals International Corporation Licenses GPCR Peptide Ligand Library Of PharmaDesign Inc. To Merck & Co., Inc. (MRK)


10/19/2005 5:12:36 PM

TOKYO, Feb. 2 /PRNewswire/ -- PharmaDesign Inc.(PDI) and its representative, Summit Pharmaceutical International Corp. (SPI), announced today, that SPI has signed an agreement with Merck & Co., Inc. to license PharmaGPEP, a GPCR peptide ligand library designed and produced by PDI. Financial and other terms were not disclosed.

PharmaDesign Inc. (PDI), http://www.pharmadesign.co.jp/, is a Tokyo based genomic drug discovery company, the first venture company of its kind in Japan, established in 1999. PharmaDesign offers a range of proprietary technologies in drug design research by utilizing their expertise in bio- informatics and in silico protein science.

Summit Pharmaceutical International Corp. (SPI), http://www.summitpharma.co.jp/, is an integrated drug discovery service company established in 1995 based in Tokyo. SPI has been the leader in providing whole range drug research support from discovery stage research materials and tools such as screening library for HTS, arrangement of research collaborations, through licensing arrangement of pharmaceutical products and candidates.

Contact: Summit Pharmaceuticals International Corp. (SPI) Katsumi Ishiguro VP & Head of Discovery Service Dept. e-mail: katsumi.ishiguro@summitpharma.co.jp Phone: +81-3-3294-1613

Summit Pharmaceuticals International Corp.

CONTACT: Katsumi Ishiguro, VP & Head of Discovery Service Dept. of SummitPharmaceuticals International Corp. (SPI), +81-3-3294-1613,katsumi.ishiguro@summitpharma.co.jp


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES